Psoriasis
Conditions
Brief summary
Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with stable disease. Study design: A pragmatic, multicentre, randomized, controlled, non-inferiority study with cost-effectiveness analysis. Study population: Patients with disease remission using normal dose of biologics. Intervention: 120 patients will be randomized into two groups: (1) dose reduction and (2) normal dose. Main study parameters/endpoints: The primary outcome is clinical effectiveness. Secondary outcomes are: health-related quality of life (HRQoL), number and time to disease flares, costs, health status, anti-drug antibody formation and serious adverse events
Detailed description
Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. These drugs have significantly improved the quality of life of psoriasis patients, but are very expensive drugs that should be used as efficiently as possible. In addition, the long-term safety profile can probably be improved if patients receive the lowest effective dose. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with stable disease: Is dose reduction non-inferior to the current practice regarding clinical effectiveness? Secondary aims are: to investigate what influence dose tapering has on quality of life, whether there are predictors for successful dose reduction, and to determine the cost-effectiveness of dose reduction. Study design: A pragmatic, multicentre, randomized, controlled, non-inferiority study with cost-effectiveness analysis. Study population: Patients who used a biologic for at least 6 months (etanercept, adalimumab, ustekinumab) can be included if they have long-term stable low disease activity. Low disease activity is defined as a PASI score (Psoriasis Area and Activity Score) \<5 and a health-related quality of life score ≤5 (Dermatology Quality of life index: DLQI). Intervention: 120 patients will be randomized into two groups: (1) dose reduction guided by PASI and DLQI (n=60, intervention) and (2) maintenance of normal dosage (n=60, usual care). Main study parameters/endpoints: The primary outcome is clinical effectiveness. Secondary outcomes are: health-related quality of life (HRQoL), number and time to disease flares, costs, health status, anti-drug antibody formation and serious adverse events
Interventions
OTHERDose decrease
Treatment strategy change: dose decrease based on PASI and DLQI
OTHERUsual care
Usual care
Sponsors
ZonMw: The Netherlands Organisation for Health Research and Development
Radboud University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomized, controlled non-inferiority study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Sustained low disease activity as described above on the dose as advised by the label. * Established diagnosis of plaque psoriasis. * Receiving treatment with adalimumab, etanercept, or ustekinumab for at least 6 months.\* * Age ≥18 years. * Ability to understand informed consent, read and answer questionnaires.
Exclusion criteria
* Psoriasis itself is not the main reason for biologic prescription (e.g. when a patient has RA and psoriasis, and RA is the main reason for the biologic). * Concomitant use of immunosuppressants other than methotrexate or acitretin for psoriasis. * Severe comorbidities with short life-expectancy (e.g. metastasized tumour). * Presumed inability to follow the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-activity | 1 year | Disease-activity measured by Psoriasis Area and Severity Index (PASI), effectiveness measure used in most psoriasis trials. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with 1 or more persistent flares | 1 year | Number of patients with 1 or more persistent flares (persistent flare is defined as at least 3 months PASI increase \>5 or DLQI \>5) |
| Disease-activity measured with HsCRP | 1 year | High-sensitivity CRP, a possible marker for disease-activity |
| Predictors for succesful dose decrease (treatment and patient characteristics) | 1 year | For both groups, patient (sex, age, PsA, comorbidities) and treatment characteristics (antibody formation, through levels of drug, dose of biologic, drug pauses, use of concomitant antipsoriatic systemic drugs (dose and duration of use), use of topical therapies during treatment (steroid class and duration of use)) will be collected. These will be used to identify predictors for successful dose reduction. |
| Anti-drug antibody levels against etanercept, adalimumab or ustekinumab | 1 year | Anti-drug antibodies (AU/mL) of the used biologic (etanercept, adalimumab or ustekinumab) will be measured using enzyme-linked immunosorbent assay or ELISA. Measures will take place at baseline and every study visit (week 0, 12, 24, 36 and 49). Anti-drug antibody levels will be used to assess whether they predict successful dose decrease. |
| Health-related quality of life (HRQoL-DLQI) | 1 year | HRQoL(Dermatology Life Quality Index (DLQI) |
| Number of serious adverse events per patient | 1 year | All serious adverse events (SAE) during study participation and their causal relation with the biologic will be assessed. |
| Costs related to medical consumption | 1 year | For cost-effectiveness analyses, questionnaires iMTA MCQ (medical consumption questionnaire) will be administered in each group at every study visit except baseline (week 12, 24, 36, 49).Data will be incorporated and presented in a cost-effectiveness analysis. |
| Costs related to productivity | 1 year | For cost-effectiveness analyses, questionnaire iMTA PCQ (productivity cost questionnaire) will be administered in each group at every study visit except baseline (week 12, 24, 36, 49).Data will be incorporated and presented in a cost-effectiveness analysis. |
| Health status (SF36) | 1 year | SF-36v2 questionnaire will be used to measure health status. Outcomes will be presented seperataly (scores for mental and physical health domain); but will also be incorporated and presented in a cost-effectiveness analysis. Questionnaire will be administered every study visit except baseline (week 12, 24, 36, 49). |
| Drug trough levels of etanercept, adalimumab or ustekinumab | 1 year | Drug trough levels (mg/l) of the used biologic (etanercept, adalimumab or ustekinumab) will be measured using enzyme-linked immunosorbent assay or ELISA. Measures will take place at baseline and every study visit (aprox. every 3 months). Anti-drug antibody levels will be used to assess whether they predict successful dose decrease. |
Countries
Netherlands
Outcome results
None listed